TP53 and non-small cell lung carcinoma: Furthermore, as p53 is inactivated in ∼50% of NSCLC tumors, and is known to repress Pol III-mediated transcription, we sought to investigate the impact of BRF2 overexpression in conjunction with p53 silencing on HBEC growth.